

# CITATION REPORT

List of articles citing

## An F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent

DOI: 10.1021/acs.jmedchem.8b00138  
Journal of Medicinal Chemistry, 2018, 61, 4103-4114.

**Source:** <https://exaly.com/paper-pdf/68946288/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
17	Novel Meta-iodobenzylguanidine-Based Copper Thiosemicarbazide-1-guanidinomethylbenzyl Anticancer Compounds Targeting Norepinephrine Transporter in Neuroblastoma. <i>Journal of Medicinal Chemistry</i> , <b>2019</b> , 62, 6985-6991	8.3	10
16	Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents. <i>ACS Omega</i> , <b>2019</b> , 4, 12584-12597	3.9	7
15	Serum proteomics analysis based on label-free revealed the protective effect of Chinese herbal formula Gu-Ben-Fang-Xiao. <i>Biomedicine and Pharmacotherapy</i> , <b>2019</b> , 119, 109390	7.5	10
14	Cytarabine (Ara-c) promotes cell apoptosis by inhibiting the phosphorylation of Protein Kinase B (AKT/PKB). <i>Process Biochemistry</i> , <b>2019</b> , 82, 144-152	4.8	
13	[F]-SuPAR: A Radiofluorinated Probe for Noninvasive Imaging of DNA Damage-Dependent Poly(ADP-ribose) Polymerase Activity. <i>Bioconjugate Chemistry</i> , <b>2019</b> , 30, 1331-1342	6.3	5
12	Research progress of F labeled small molecule positron emission tomography (PET) imaging agents. <i>European Journal of Medicinal Chemistry</i> , <b>2020</b> , 205, 112629	6.8	4
11	[F]AZD2461, an Insight on Difference in PARP Binding Profiles for DNA Damage Response PET Imaging. <i>Molecular Imaging and Biology</i> , <b>2020</b> , 22, 1226-1234	3.8	3
10	A one-pot radiosynthesis of [F]PARPi. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2020</b> , 63, 419-425	1.9	3
9	Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	11
8	Molecular Imaging: PARP-1 and Beyond. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 765-770	8.9	3
7	Two experts and a newbie: [F]PARPi vs [F]FTT vs [F]FPyPARP-a comparison of PARP imaging agents. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 1	8.8	1
6	A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma. <i>Theranostics</i> , <b>2021</b> , 11, 7911-7947	12.1	5
5	DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
4	Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	0
3	Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours. <b>2022</b> , 242, 114690		0
2	PARP targeted Auger emitter therapy with [125I]PARPi-01 for triple-negative breast cancer. <b>2022</b> , 12,		0
1	Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases. 9,		0

